A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety, tolerability and PK profile of
HMPL-295S1 and determine MTD and/or RP2D in patients with advanced malignant solid tumor. It
will be extended to enroll 10-15 patients at this dose after RP2D is determined, as to
further evaluate the safety of RP2D and the preliminary efficacy of HMPL-295S1. In addition,
an exploratory study on the pharmacokinetic biomarkers of HMPL-295S1 is planned in this
study.